However, this assumption is not based on solid data, and the prognostic impact of additional molecular abnormalities (such as the MDS-related mutations) on the outcomes of patients with NPM1mut and/or FLT3-ITD AML is still a matter of debate. This evidence concerns the gene FLT3 and myelodysplastic syndrome.